The FDA on March 7, 2024, granted accelerated approval to BRUKINSA® with Obinutuzumab for Relapsed or Refractory Follicular Lymphoma (FL) after two or more lines of systemic therapy. BRUKINSA® is a product of BeiGene USA, Inc.
Bottom Ad
Advertisement
Subscribe
